Quantitative Models of the Dose-Response and Time Course of Inhalational Anthrax in Humans

PLoS Pathogens

Volumn 9, Issue 8, 2013, Pages

  Toth, Damon J A ^a,b,c   Gundlapalli, Adi V ^a,c   Schell, Wiley A ^d   Bulmahn, Kenneth ^e   Walton, Thomas E ^f   Woods, Christopher W ^d   Coghill, Catherine ^g   Gallegos, Frank ^g   Samore, Matthew H ^a,c   Adler, Frederick R ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Independent Risk Assessment Contractor   (United States)

^f CENTERS FOR EPIDEMIOLOGY AND ANIMAL HEALTH   (United States)

^g Independent Risk Assessment Contractor   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTHRAX; ARTICLE; AUTOPSY; BACILLUS ANTHRACIS; BACTERIAL CLEARANCE; BACTERIAL LOAD; BACTERIAL SPORE; BREATHING RATE; COMPUTER PROGRAM; DEATH; DISEASE COURSE; EXPOSURE; HUMAN; INCUBATION TIME; INFECTION RATE; LETHAL DOSE; MODEL; NONHUMAN; PROPHYLAXIS; RISK ASSESSMENT; SIMULATION; SVERDLOVSK ANTHRAX OUTBREAK; TREATMENT DURATION;

ADMINISTRATION, INHALATION; ANTHRAX; ANTI-BACTERIAL AGENTS; BACILLUS ANTHRACIS; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; TIME FACTORS; UNITED STATES;

EID: 84883417733     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003555     Document Type: Article

References (57)

1. Henderson DA, (1999) The looming threat of bioterrorism. Science 283: 1279-1282.
2. Webb GF, (2003) A silent bomb: the risk of anthrax as a weapon of mass destruction. Proc Natl Acad Sci USA 100: 4355-4356.
3. World Health Organization (2008) Anthrax in Humans and Animals. Geneva: WHO Press. 208 p.
4. Centers for Disease Control and Prevention (CDC) (2010) Gastrointestinal anthrax after an animal-hide drumming event- New Hampshire and Massachusetts, 2009. MMWR Morb Mortal Wkly Rep 59: 872-877.
5. Booth MG, Hood J, Brooks TJ, Hart A, (2010) Anthrax infection in drug users. Lancet 375: 1345-1346.
6. Guh A, Heyman ML, Barden D, Fontana J, Hadler JL, (2010) Lessons learned from the investigation of a cluster of cutaneous anthrax cases in Connecticut. J Public Health Manag Pract 16: 201-210.
7. Meselson M, Guillemin J, Hugh-Jones M, Langmuir A, Popova I, et al. (1994) The Sverdlovsk anthrax outbreak of 1979. Science 266: 1202-1208.
8. Greene CM, Reefhuis J, Tan C, Fiore AE, Goldstein S, et al. (2002) Epidemiologic investigations of bioterrorism-related anthrax, New Jersey, 2001. Emerg Infect Dis 8: 1048-1055.
9. Wein LM, Craft DL, Kaplan EH, (2003) Emergency response to an anthrax attack. Proc Natl Acad Sci USA 100: 4346-4351.
10. Craft DL, Wein LM, Wilkens AH, (2005) Analyzing bioterror response logistics: The case of anthrax. Management Science 51: 679-694.
11. Isukapalli SS, Lioy PJ, Georgopoulos PG, (2008) Mechanistic modeling of emergency events: assessing the impact of hypothetical releases of anthrax. Risk Anal 28: 723-740.
12. IOM (Institute of Medicine) (2012) Prepositioning antibiotics for anthrax. Washington, DC: National Academies Press. 343 p.
13. United States Government Accountability Office (2005) Anthrax detection: agencies need to validate sampling activities in order to increase confidence in negative results. Washington, DC: United States Government Accountability Office. 113 p.
14. United States Government Accountability Office (2012) Anthrax: DHS faces challenges in validating methods for sample collection and analysis. Washington, D.C.: United States Government Accountability Office. 108 p.
15. Wilkening DA, (2006) Sverdlovsk revisited: modeling human inhalation anthrax. Proc Natl Acad Sci USA 103: 7589-7594.
16. Webb GF, Blaser MJ, (2002) Mailborne transmission of anthrax: Modeling and implications. Proc Natl Acad Sci USA 99: 7027-7032.
17. Cohen ML, Whalen T, (2007) Implications of low level human exposure to respirable B. anthracis. Applied Biosafety 12: 109-115.
18. Haas CN, (2002) On the risk of mortality to primates exposed to anthrax spores. Risk Anal 22: 189-193.
19. Bartrand TA, Weir MH, Haas CN, (2008) Dose-response models for inhalation of Bacillus anthracis spores: interspecies comparisons. Risk Anal 28: 1115-1124.
20. Coleman ME, Thran B, Morse SS, Hugh-Jones M, Massulik S, (2008) Inhalation anthrax: dose response and risk analysis. Biosecur Bioterror 6: 147-160.
21. Hong T, Gurian PL, Huang Y, Haas CN, (2012) Prioritizing risks and uncertainties from intentional release of selected Category A pathogens. PLoS One 7: e32732.
22. Fennelly KP, Davidow AL, Miller SL, Connell N, Ellner JJ, (2004) Airborne infection with Bacillus anthracis-from mills to mail. Emerg Infect Dis 10: 996-1002.
23. Dahlgren CM, Buchanan LM, Decker HM, Freed SW, Phillips CR, et al. (1960) Bacillus anthracis aerosols in goat hair processing mills. Am J Hyg 72: 24-31.
24. Brachman PS, Kaufman AF, Dalldorf FG, (1966) Industrial inhalation Anthrax. Bacteriol Rev 30: 646-659.
25. Holty JE, Bravata DM, Liu H, Olshen RA, McDonald KM, et al. (2006) Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 144: 270-280.
26. Glassman HN, (1966) Discussion. Bacteriol Rev 30: 657-659.
27. Druett HA, Henderson DW, Packman L, Peacock S, (1953) Studies on respiratory infection. I. The influence of particle size on respiratory infection with anthrax spores. J Hyg (Lond) 51: 359-371.
28. Haas CN, (1996) How to average microbial densities to characterize risk. Water Research 30: 1036-1038.
29. Franz DR, Jahrling PB, Friedlander AM, McClain DJ, Hoover DL, et al. (1997) Clinical recognition and management of patients exposed to biological warfare agents. JAMA 278: 399-411.
30. United States Army Medical Research Institute of Infectious Diseases (2011) USAMRIID's Medical Management of Biological Casualties Handbook. Washington, DC: US Government Printing Office. 269 p.
31. Rickmeier GL, McClellan GE, Anno GA, (2001) Biological warfare human response modeling. Military Operations Research 6: 35-57.
32. Brookmeyer R, Johnson E, Barry S, (2005) Modelling the incubation period of anthrax. Stat Med 24: 531-542.
33. Haas CN, Rose JB, Gerba CP (1999) Quantitative Microbial Risk Assessment. New York: John Wiley and Sons. 464 p.
34. Henderson DW, Peacock S, Belton FC, (1956) Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg (Lond) 54: 28-36.
35. Mayer BT, Koopman JS, Ionides EL, Pujol JM, Eisenberg JN, (2011) A dynamic dose-response model to account for exposure patterns in risk assessment: a case study in inhalation anthrax. J R Soc Interface 8: 506-517.
36. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH, (1993) Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A 90: 2291-2294.
37. Wilkening DA, (2008) Modeling the incubation period of inhalational anthrax. Med Decis Making 28: 593-605.
38. Brookmeyer R, Blades N, Hugh-Jones M, Henderson DA, (2001) The statistical analysis of truncated data: application to the Sverdlovsk anthrax outbreak. Biostatistics 2: 233-247.
39. Brookmeyer R, Johnson E, Bollinger R, (2003) Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak. Proc Natl Acad Sci USA 100: 10129-10132.
40. Centers for Disease Control and Prevention (2001) Update: Investigation of bioterrorism-related anthrax, 2001. MMWR Morb Mortal Wkly Rep 50: 1008-1010.
41. Fukao T, (2004) Immune system paralysis by anthrax lethal toxin: the roles of innate and adaptive immunity. Lancet Infect Dis 4: 166-170.
42. Pujol JM, Eisenberg JE, Haas CN, Koopman JS, (2009) The effect of ongoing exposure dynamics in dose response relationships. PLoS Comput Biol 5: e1000399.
43. Tournier JN, Rossi Paccani S, Quesnel-Hellmann A, Baldari CT, (2009) Anthrax toxins: a weapon to systematically dismantle the host immune defenses. Mol Aspects Med 30: 456-466.
44. Jefferds MD, Laserson K, Fry AM, Roy S, Hayslett J, et al. (2002) Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, D.C., 2001. Emerg Infect Dis 8: 1138-1144.
45. SteelFisher G, Blendon R, Ross LJ, Collins BC, Ben-Porath EN, et al. (2011) Public response to an anthrax attack: reactions to mass prophylaxis in a scenario involving inhalation anthrax from an unidentified source. Biosecur Bioterror 9: 239-250.
46. Drusano GL, Okusanya OO, Okusanya A, Van Scoy B, Brown DL, et al. (2008) Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis? Antimicrob Agents Chemother 52: 3973-3979.
47. Gutting BW, Nichols TL, Channel SR, Gearhart JM, Andrews GA, et al. (2012) Inhalational anthrax (Ames aerosol) in naive and vaccinated New Zealand rabbits: characterizing the spread of bacteria from lung deposition to bacteremia. Front Cell Infect Microbiol 2: 87.
48. Barnewall RE, Comer JE, Miller BD, Gutting BW, Wolfe DN, et al. (2012) Achieving consistent multiple daily low-dose Bacillus anthracis spore inhalation exposures in the rabbit model. Front Cell Infect Microbiol 2: 71.
49. Twenhafel NA, (2010) Pathology of inhalational anthrax animal models. Vet Pathol 47: 819-830.
50. R Core Team (2013) R: A Language and Environment for Statistical Computing. Vienna, Austria.
51. Bliss CI, (1934) The Method of Probits. Science 79: 38-39.
52. Finney DJ (1947) Probit Analysis. Cambridge, UK: Cambridge University Press. 272 p.
53. Tamrakar SB, Haas CN, (2008) Dose-response model for Burkholderia pseudomallei (melioidosis). J Appl Microbiol 105: 1361-1371.
54. Furumoto WA, Mickey R, (1967) A mathematical model for the infectivity-dilution curve of tobacco mosaic virus: experimental tests. Virology 32: 224-233.
55. Teunis PF, Havelaar AH, (2000) The Beta Poisson dose-response model is not a single-hit model. Risk Anal 20: 513-520.
56. Brandeau ML, McCoy JH, Hupert N, Holty JE, Bravata DM, (2009) Recommendations for modeling disaster responses in public health and medicine: a position paper of the society for medical decision making. Med Decis Making 29: 438-460.
57. Huang Y, Haas CN, (2011) Quantification of the relationship between bacterial kinetics and host response for monkeys exposed to aerosolized Francisella tularensis. Appl Environ Microbiol 77: 485-490.